Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to study whether daily treatment with liraglutide improves
insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide
treatment is tolerable and safe in subjects aged 10-30 years, having an early diagnosis of
type 1 diabetes (no symptoms, diagnosis in OGTT), and treated with insulin.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oulu
Collaborators:
Oulu University Hospital Skane University Hospital Tampere University Hospital Turku University Hospital